Publications by authors named "Tomoko Sonezaki"
JCO Precis Oncol
November 2020
Article Synopsis
- Several trials suggest that analyzing circulating tumor DNA (ctDNA) can help predict which metastatic colorectal cancer (mCRC) patients might benefit from rechallenge treatment with anti-EGFR monoclonal antibodies.
- Patients from two phase II trials were evaluated, revealing a disease control rate of 62.5%, but with no overall responses; those with mutations in ctDNA had a significantly lower disease control rate and shorter survival times.
- The study highlights the potential importance of ctDNA status in guiding rechallenge treatment decisions for mCRC, emphasizing its value in clinical practice.
